Repligen Corp at JPMorgan Healthcare Conference Transcript
Perfect. Good afternoon, everyone. This is Rachel Vatnsdal with the Life Science Tools and Diagnostics team. I'm joined today by Tony Hunt, CEO of Repligen. So this presentation will be 40 minutes. The first 20 minutes or so will be a presentation, followed by 20 minutes of Q&A. If any of you in the audience have questions, please feel free to either submit them on the app or you can ping me and reach out directly. With that, I will pass it off to Tony.
Great. Thanks, Rachel, and great to be here and appreciate getting an opportunity to talk about Repligen at JPMorgan again. I'm going to spend maybe 5 minutes, trying to address maybe some of the -- what's happening in the bioprocessing industry in 2023. I'm not going to give guidance on 2024, so sorry on disappointing people on that one. But I do think that it's important kind of to get our perspective on where we think the bioprocessing industry is as we jump into
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |